Trial Profile
RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 23 Jan 2013 Planned end date changed from 1 Nov 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 23 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.